MGNX
BEARISH
$3.47
Live
MacroGenics, Inc. · NASDAQ
Target $4.8
(+38.3%)
$1.1
52W Range
$3.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$220.55M
P/E
N/A
ROE
-86.9%
Profit margin
-49.9%
Debt/Equity
0.66
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.
Key Strengths
Exceptional YoY revenue growth of 113%
Strong short-term liquidity with a Current Ratio of 5.10
Manageable Debt/Equity ratio of 0.66
Significant recent price momentum (+173.2% 1Y)
Positive analyst sentiment with a target price of $4.80
Key Risks
Critical fundamental health (Piotroski F-Score 0/9)
Negative gross margins (-22.53%) indicating an unsustainable cost structure
Severe earnings volatility and frequent misses (Average surprise -286.67%)
Deeply negative ROE (-86.94%) and Profit Margin (-49.91%)
Long-term value destruction with a 5-year price change of -88.9%
AI Fair Value Estimate
Based on comprehensive analysis
$3.1
-10.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
20
75
15
10
0
AI Verdict
Speculative High-Risk
Key drivers: Triple-digit revenue growth, Catastrophic Piotroski score, Strong liquidity runway, Negative gross margins
Confidence
90%
Value
20/100
P/E is N/A; valuation is purely speculative based on growth
Positives
- Low Price/Sales ratio (1.48)
Watchpoints
- No Graham Number due to lack of earnings
- High Price/Book (3.95) for a non-profitable entity
Future
75/100
Growth is the primary driver, but monetization is absent
Positives
- 113% YoY Revenue Growth
- 132.53% Q/Q Revenue Growth
Watchpoints
- Negative forward P/E (-3.58)
Past
15/100
Historical trend shows long-term capital erosion
Positives
- Recent 1Y recovery
Watchpoints
- 5Y return of -88.9%
- Consistent failure to meet EPS estimates
Health
10/100
Piotroski score indicates maximum fundamental weakness
Positives
- High Current Ratio (5.10)
Watchpoints
- Piotroski F-Score 0/9
- Negative ROA and ROE
Dividend
0/100
Typical for early-stage biotech
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.47
Analyst Target
$4.8
Upside/Downside
+38.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MGNX and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
Primary
|
-88.9% | -46.5% | +173.2% | +111.6% | +15.7% | +9.1% |
|
CVRX
CVRx, Inc.
Peer
|
-70.1% | -7.4% | -27.5% | -4.1% | +6.5% | -11.5% |
|
LUCD
Lucid Diagnostics Inc.
Peer
|
-89.1% | -5.9% | +7.6% | +8.5% | -6.6% | +13.3% |
|
MDWD
MediWound Ltd.
Peer
|
-51.4% | +35.6% | +6.4% | -3.1% | +6.5% | +6.8% |
|
MENS
Jyong Biotech Ltd.
Peer
|
-72.4% | -72.4% | -72.4% | -95.0% | +40.9% | +13.0% |
MGN
MacroGenics, Inc.
Primary
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
CVR
CVRx, Inc.
Peer
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
LUC
Lucid Diagnostics Inc.
Peer
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%
MDW
MediWound Ltd.
Peer
5Y
-51.4%
3Y
+35.6%
1Y
+6.4%
6M
-3.1%
1M
+6.5%
1W
+6.8%
MEN
Jyong Biotech Ltd.
Peer
5Y
-72.4%
3Y
-72.4%
1Y
-72.4%
6M
-95.0%
1M
+40.9%
1W
+13.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.58
PEG Ratio
N/A
P/B Ratio
3.95
P/S Ratio
1.48
EV/Revenue
0.45
EV/EBITDA
-1.03
Market Cap
$220.55M
Profitability
Profit margins and return metrics
Profit Margin
-49.91%
Operating Margin
-29.34%
Gross Margin
-22.53%
ROE
-86.94%
ROA
-17.56%
Growth
Revenue and earnings growth rates
Revenue Growth
+113.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+132.53%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.66
Moderate
Current Ratio
5.1
Strong
Quick Ratio
4.71
Excellent
Cash/Share
$2.99
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
75.5%
Op. Margin
-29.3%
Net Margin
-34.3%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
3.62x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
99%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-09
$-0.22
-1000.0% surprise
2025-11-12
$0.27
+161.2% surprise
2025-08-14
$-0.57
-21.2% surprise
Healthcare Sector Comparison
Comparing MGNX against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-86.94%
This Stock
vs
-86.0%
Sector Avg
+1.1%
(Above Avg)
Profit Margin
-49.91%
This Stock
vs
-11.76%
Sector Avg
+324.5%
(Superior)
Debt to Equity
0.66
This Stock
vs
3.51
Sector Avg
-81.1%
(Less Debt)
Revenue Growth
113.0%
This Stock
vs
90.15%
Sector Avg
+25.3%
(Fast Growth)
Current Ratio
5.1
This Stock
vs
3.67
Sector Avg
+39.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MGNX
MacroGenics, Inc.
|
BEARISH | $220.55M | - | -86.9% | -49.9% | $3.47 | |
|
CVRX
CVRx, Inc.
|
BEARISH | $220.23M | - | -96.6% | -94.1% | $8.37 | Compare |
|
LUCD
Lucid Diagnostics Inc.
|
BEARISH | $218.06M | - | -710.6% | -% | $1.28 | Compare |
|
MDWD
MediWound Ltd.
|
BEARISH | $226.84M | - | -63.9% | -140.8% | $17.65 | Compare |
|
MENS
Jyong Biotech Ltd.
|
BEARISH | $212.12M | - | -% | -% | $2.79 | Compare |
MGNX
MacroGenics, Inc.
BEARISH
Mkt Cap
$221M
P/E
-
ROE
-86.9%
Price
$3.47
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-13 | KARRELS JAMES | Chief Financial Officer | Stock Award | 14,999 | - |
| 2026-02-13 | KOENIG SCOTT | Director | Stock Award | 21,165 | - |
| 2026-02-13 | BONVINI EZIO | Officer | Stock Award | 16,665 | - |
| 2026-02-13 | RISSER ERIC BLASIUS | Chief Executive Officer | Stock Award | 16,665 | - |
| 2026-02-13 | SPITZNAGEL THOMAS | Officer | Stock Award | 13,332 | - |
| 2026-02-13 | PETERS JEFFREY STUART | General Counsel | Stock Award | 13,332 | - |
| 2026-02-13 | SMITH BETH ANN | Officer and Treasurer | Stock Award | 1,095 | - |
| 2026-02-06 | KARRELS JAMES | Chief Financial Officer | Stock Award | 16,333 | - |
| 2026-02-06 | KOENIG SCOTT | Director | Stock Award | 15,831 | - |
| 2026-02-06 | BONVINI EZIO | Officer | Stock Award | 18,167 | - |
| 2026-02-06 | RISSER ERIC BLASIUS | Chief Executive Officer | Stock Award | 17,834 | - |
| 2026-02-06 | SPITZNAGEL THOMAS | Officer | Stock Award | 15,000 | - |
| 2026-02-06 | PETERS JEFFREY STUART | General Counsel | Stock Award | 15,000 | - |
| 2026-02-06 | SMITH BETH ANN | Officer and Treasurer | Stock Award | 4,200 | - |
KARRELS JAMES
Chief Financial Officer
2026-02-13
14,999 shares
KOENIG SCOTT
Director
2026-02-13
21,165 shares
BONVINI EZIO
Officer
2026-02-13
16,665 shares
RISSER ERIC BLASIUS
Chief Executive Officer
2026-02-13
16,665 shares
SPITZNAGEL THOMAS
Officer
2026-02-13
13,332 shares
PETERS JEFFREY STUART
General Counsel
2026-02-13
13,332 shares
SMITH BETH ANN
Officer and Treasurer
2026-02-13
1,095 shares
KARRELS JAMES
Chief Financial Officer
2026-02-06
16,333 shares
KOENIG SCOTT
Director
2026-02-06
15,831 shares
BONVINI EZIO
Officer
2026-02-06
18,167 shares
RISSER ERIC BLASIUS
Chief Executive Officer
2026-02-06
17,834 shares
SPITZNAGEL THOMAS
Officer
2026-02-06
15,000 shares
PETERS JEFFREY STUART
General Counsel
2026-02-06
15,000 shares
SMITH BETH ANN
Officer and Treasurer
2026-02-06
4,200 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
5 analysts
B. Riley Securities
2026-04-10
Neutral
Buy
Barclays
2026-03-10
Overweight
Overweight
HC Wainwright & Co.
2025-11-03
Neutral
Neutral
Past News Coverage
Recent headlines mentioning MGNX from our newsroom.
Newest → oldest
No matching news yet.